Global Custom Market Research Reports Provider Company

phone

Restless Legs Syndrome - Pipeline Review, H2 2018

  • Published Date: 10 Jul 2018
  • Number of Pages: 43
  • Category: Pharmaceuticals
  • Country: Global
Restless Legs Syndrome - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2018, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calfs or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 3 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restless Legs Syndrome - Overview
Restless Legs Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Restless Legs Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Restless Legs Syndrome - Companies Involved in Therapeutics Development
Bioprojet SCR
Galenica Ltd
Hisamitsu Pharmaceutical Co Inc
Merz Pharma GmbH & Co KgaA
Omeros Corp
Serina Therapeutics Inc
Restless Legs Syndrome - Drug Profiles
(cannabidiol + dronabinol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cannabidiol + gabapentin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aplindore fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-1.4979 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropinirole hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SER-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Restless Legs Syndrome - Dormant Projects
Restless Legs Syndrome - Discontinued Products
Restless Legs Syndrome - Product Development Milestones
Featured News & Press Releases
Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinsons Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Restless Legs Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Restless Legs Syndrome - Pipeline by Bioprojet SCR, H2 2018
Restless Legs Syndrome - Pipeline by Galenica Ltd, H2 2018
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2018
Restless Legs Syndrome - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2018
Restless Legs Syndrome - Pipeline by Omeros Corp, H2 2018
Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, H2 2018
Restless Legs Syndrome - Dormant Projects, H2 2018
Restless Legs Syndrome - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Restless Legs Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018 According to the recently published report Transmembrane Prolyl 4 Hydroxylase -

View Report

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018 CD40 Ligand (T

View Report

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2018 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports